Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.

University at Buffalo (UB)

Status: Completed

Conditions: Parkinson's Disease

Treatments: Drug: Rasagiline

Study type: Observational

Funder types: Other

Identifiers

NCT02278588

[616856-4]

Details and patient eligibility

About

In this investigator-initiated study, we will compare changes in brain cognitive biomarkers assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B inhibitors and 25 age-matched healthy controls. Will also compare the changes in Mini-Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA) scores and plasma brain-derived neurotrophic factor (BDNF) with changes in brain cognitive biomarkers in all IPD patients and HC over 2.5 years.

Enrollment: 45 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

IPD or HC subjects who were enrolled in a similar study about 2.5 years ago and for whom Baseline DTI data are available.

Trial design

45 participants in 3 patient groups

PD-R

Description:

Parkinson's disease receiving rasagiline

Treatment:

Drug: Rasagiline

PD-NMAO

Description:

Parkinson's disease not receiving any MAO-B inhibitors

HC

Description:

Healthy Controls